Targeting Core

瞄准核心

• 批准号: 7983111
• 负责人: David G Gorenstein
• 金额: $ 18.19万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-01 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7983111
• 关键词: Affinity; Amino Acids; Antibodies; Aptamer Technology; Area; Binding; Binding Proteins; Biological; Biological Markers; CCNE1 gene; CD44 gene; Cell Membrane Proteins; Cell surface; Cells; Chemistry; Complex; Diversity Library; E-Selectin; Epidermal Growth Factor Receptor; Exhibits; Gold; HIV-1; In Vitro; Intercellular adhesion molecule 1; Legal patent; Libraries; Life; Ligands; Methods; Modification; Molecular Weight; Nucleic Acid Folding; Nucleic Acids; Nucleocapsid; Oligonucleotides; Oxygen; Peptide antibodies; Peptide aptamers; Peptides; Phage Display; Pharmaceutical Preparations; Phosphorothioate Oligonucleotide; Preparation; Property; Proteins; Publications; RNA; Reagent; Resources; Ricin; Side; Solutions; Specificity; Stem cells; Structure; Sulfur; Surface; Technology; Temperature; Time; Toxin; Vertebral column; analog; aptamer; base; cancer stem cell; combinatorial; cost; env Gene Products; functional group; immunogenicity; inorganic phosphate; interest; meetings; nanoparticle; next generation; novel; nuclease; phosphate ester; scaffold; small molecule; thiophosphate

CORE TITLE: Targeting Core CORE SUMMARY: Traditionally, robust protein-specific targeting ligand requirements are met by antibodies (Abs). Antibodies however often have significant problems, including high cost, selection difficulties, selectivity problems, preparation difficulties, stability and immunogenicity. The Targeting Core objective is to provide the Projects in the TCCN sets of targeting reagents for the nanoparticles that not only includes "gold standard" antibodies but novel aptamers and peptides to both endothelial, cancer and stem cells, both to specific cell surface ligands as well as the cells themselves. All projects will use the resources from the Biological Targeting Core. Specifically, the Targeting Core will develop thioaptamers and next-generation Xaptamers for targeting nanoparticles to CD44 (Project 1; Aim 2), E-Selectin, (Project 1: Aim 2, Project 2: Aim 2), VGFR, EGFR, ICAM-1 and cells (Project 3: Aim 1) and peptides and antibodies via phage display for targeting proteins (Project 1; Aim 2) and cells (Project 3: Aim 1; Project 4: Aim 2). Additionally, the Targeting Core will provide conjugation of targeting ligands and all micro/nanoparticles (Projects 1-3).

核心标题：瞄准核心 核心摘要：传统上，抗体（Abs）满足稳健的蛋白质特异性靶向配体要求。然而，抗体通常具有显著的问题，包括高成本、选择困难、选择性问题、制备困难、稳定性和免疫原性。靶向核心目标是为纳米颗粒提供TCCN靶向试剂组中的项目，这些纳米颗粒不仅包括“金标准”抗体，还包括针对内皮细胞、癌症细胞和干细胞的新型适体和肽，既针对特定的细胞表面配体，也针对细胞本身。所有项目都将使用生物靶向核心的资源。具体来说，靶向核心将开发硫代适体和下一代Xaptamers，用于将纳米颗粒靶向CD 44（项目1;目标2），E-选择素，（项目1：目标2，项目2：目标2）、VGFR、EGFR、ICAM-1和细胞（项目3：Aim 1）和肽和抗体通过噬菌体展示用于靶向蛋白质（项目1; Aim 2）和细胞（项目3：Aim 1;项目4：Aim 2）。此外，靶向核心将提供靶向配体和所有微米/纳米颗粒的缀合（项目1-3）。